Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea
Authors' conclusion
The study suggests phentermine/topiramate ER is an effective option for obesity management in a South Korean population, though long-term adherence remains a challenge.
Study context
- Population
- People with obesity initiating phentermine/topiramate extended release (ER), January 2020–April 2023, 10 tertiary hospitals in South Korea540 men · 1,299 women
- Participants
- 1,839 people
- Outcome
- Body weight change
- Follow-up
- 5-6 months
Methodological detailsmulticentre, 10 tertiary hospitals, routine clinical practice
- Multicentre
- 10 tertiary hospitals
- Routine clinical practice
Main finding
As reported in the abstract
Weight reduction
- Mean weight reduction
- 7.9%
- Weight loss in men
- 7.1%
- Weight loss in women
- 8.2%
- Achieved >5% weight loss
- Over 56%
- Exceeded 10% reduction
- 23%
- Continuation rate at 5-6 months
- 48%
Observational data: associations, not effects.
Further findings
Predictors of weight loss
- Younger participants, women and those with moderate to severe obesity had more pronounced weight loss vs older men and mild obesity, respectively
Metabolic parameters · 5-6 months
- HbA1c decrease (%)
- 0.4 ± 0.9%; p < 0.001
- LDL-C decrease (mg/dL)
- 10 ± 32 mg/dL; p < 0.001
- Systolic blood pressure decrease (mmHg)
- 6 ± 15 mmHg; p < 0.001
Weight loss in those persisting in treatment · 12 months
- Persisted in treatment
- 21%
- Average weight loss
- 9.6%
- Surpassed 5% weight loss
- 65%
Safety
- Mild adverse events (e.g. paresthesia, dry mouth, insomnia)
- 15%
- Treatment was well-tolerated
Original publication
Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea. Diabetes Obes Metab. Published 17 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →